Literature DB >> 8722542

Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice.

P Russell1, S M Eley, D L Bell, R J Manchee, R W Titball.   

Abstract

The efficacy of doxycycline and ciprofloxacin against an experimental plague infection was assessed by comparing the median lethal dose (MLD) of Yersinia pestis in antibiotic-treated and untreated mice. The MLD of Y. pestis GB strain in untreated mice by the intra-peritoneal route was 23 cfu. If ciprofloxacin dosage (20 or 40 mg/kg twice daily) was initiated 48 h before infection, it afforded complete protection against an intra-peritoneal challenge of 5.24 x 10(7) cfu. Ciprofloxacin therapy initiated 24 h post-challenge was less protective, the MLD was raised to 2.0 x 10(5) and 2.2 x 10(5) cfu for 40 and 20 mg/kg respectively. Doxycycline dosage (40 mg/kg twice daily) initiated 48 h prior to infection raised the MLD to 1.6 x 10(4) cfu, but other prophylactic and therapeutic regimes were ineffective against challenges greater than 6.76 x 10(2) cfu. Ciprofloxacin may therefore be a useful antibiotic to consider for the treatment of plague.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8722542     DOI: 10.1093/jac/37.4.769

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Biological Warfare: Implications for Antimicrobial Use.

Authors:  Ethan Rubinstein; Itzhak Levi
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

2.  Pulmonary Manifestations of Bioterrorism.

Authors:  Renuka Heddurshetti; Wadchara Pumpradit; Larry I. Lutwick
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

3.  Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.

Authors:  A Louie; H S Heine; B VanScoy; A Eichas; K Files; S Fikes; D L Brown; W Liu; M Kinzig-Schippers; F Sörgel; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

4.  The African Green Monkey Model of Pneumonic Plague and US Food and Drug Administration Approval of Antimicrobials Under the Animal Rule.

Authors:  Judith A Hewitt; Lynda L Lanning; Joseph L Campbell
Journal:  Clin Infect Dis       Date:  2020-05-21       Impact factor: 9.079

5.  Antibiotic treatment of experimental pneumonic plague in mice.

Authors:  W R Byrne; S L Welkos; M L Pitt; K J Davis; R P Brueckner; J W Ezzell; G O Nelson; J R Vaccaro; L C Battersby; A M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus.

Authors:  J A Frean; L Arntzen; T Capper; A Bryskier; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

7.  Lovastatin protects against experimental plague in mice.

Authors:  Saravanan Ayyadurai; Hubert Lepidi; Claude Nappez; Didier Raoult; Michel Drancourt
Journal:  PLoS One       Date:  2010-06-02       Impact factor: 3.240

8.  Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.

Authors:  Arnold Louie; Mark R Deziel; Weiguo Liu; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

9.  Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.

Authors:  Johnny W Peterson; Scott T Moen; Daniel Healy; Jennifer E Pawlik; Joanna Taormina; Jason Hardcastle; John M Thomas; William S Lawrence; Cindy Ponce; Bagram M Chatuev; Bryan T Gnade; Sheri M Foltz; Stacy L Agar; Jian Sha; Gary R Klimpel; Michelle L Kirtley; Tonyia Eaves-Pyles; Ashok K Chopra
Journal:  Open Microbiol J       Date:  2010-06-03

Review 10.  Antibiotic Therapy of Plague: A Review.

Authors:  Florent Sebbane; Nadine Lemaître
Journal:  Biomolecules       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.